Analyse des Mineral-Puffer-Systems des Blutes

ZUSAMMENFASSUNG

Ein neuer Ansatz zur Beurteilung des CKD-MBD-Syndroms (CKD-MBD: „chronic kidney disease – mineral bone disorder“) ist die Messung des Mineral-Puffer-Systems des Blutes. Mittels der Messung von endogenen Kalziproteinpartikeln (CPP: „calciprotein particles“) und der Bestimmung der CPP-Kristallisations-Zeit ex vivo (T50-Test) kann der Gesamtzustand des Mineral-Puffer-Systems des Blutes festgestellt werden. In Zukunft könnte die Optimierung des Mineral-Puffer-Systems die bisherigen Parameter – Phosphat, Kalzium, Parathormon (PTH) – ersetzen. Entsprechende klinische Studien sind allerdings noch erforderlich.

Publication History

Article published online:
12 December 2024

• Literatur

• 1 European Renal Association (ERA) Registry. ERA Registry Annual Report 2020. Im Internet:. https://www.era-online.org/wp-content/uploads/2022/12/ERA-Registry-Annual-Report2020.pdf Stand: 25.09.2024
• 2 Naylor KL, Kim SJ, McArthur E. et al Mortality in incident maintenance dialysis patients versus incident solid organ cancer patients: a population-based cohort. Am J Kidney Dis 2019; 73: 765-776
• 3 United States Renal Data System. 2023 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Im Internet:. https://usrds-adr.niddk.nih.gov/2023 Stand: 25.09.2024
• 4 Wanner C, Krane V, Marz W. et al Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
• 5 Fellström BC, Jardine AG, Schmieder RE. et al Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
• 6 Baigent C, Landray MJ, Reith C. et al The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
• 7 Cholesterol Treatment Trialists C. Herrington WG, Emberson J. et al Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4: 829-839
• 8 Juurlink DN, Mamdani MM, Lee DS. et al Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004; 351: 543-551
• 9 Lam NN, Jain AK, Hackam DG. et al Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney Int 2009; 76: 1172-1179
• 10 Goodman WG, Goldin J, Kuizon BD. et al Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
• 11 Schwarz U, Buzello M, Ritz E. et al Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223
• 12 Blacher J, Guerin AP, Pannier B. et al Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942
• 13 Massy ZA, Merkling T, Wagner S. et al Association of serum phosphate with efficacy of statin therapy in hemodialysis patients. Clin J Am Soc Nephrol 2022; 17: 546-554
• 14 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113) S1-S130
• 15 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011) 2017; 7: 1-59
• 16 Chertow GM, Block GA, Correa-Rotter R. et al Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
• 17 Suki WN, Zabaneh R, Cangiano JL. et al Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
• 18 Di Iorio B, Molony D, Bell C. et al Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62: 771-778
• 19 Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP. et al Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant 2015; 30: 1542-1551
• 20 Lamina C, Kronenberg F, Stenvinkel P. et al Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort. Nephrol Dial Transplant 2020; 35: 478-487
• 21 Koshikawa S, Akizawa T, Kurokawa K. et al Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses. Nephron 2002; 90: 413-423
• 22 Gaede P, Vedel P, Larsen N. et al Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
• 23 Heiss A, DuChesne A, Denecke B. et al Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 278: 13333-13341
• 24 Ketteler M, Bongartz P, Westenfeld R. et al Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833
• 25 Cai MM, Smith ER, Holt SG. The role of fetuin-A in mineral trafficking and deposition. Bonekey Rep 2015; 4: 672
• 26 Schafer C, Heiss A, Schwarz A. et al The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366
• 27 Smith ER, Hewitson TD, Jahnen-Dechent W. Calciprotein particles: mineral behaving badly?. Curr Opin Nephrol Hypertens 2020; 29: 378-386
• 28 Aghagolzadeh P, Bachtler M, Bijarnia R. et al Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis 2016; 251: 404-414
• 29 Thiem U, Hewitson TD, Toussaint ND. et al Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells. Nephrol Dial Transplant 2023; 38: 1282-1296
• 30 Smith ER, Hewitson TD, Hanssen E. et al Biochemical transformation of calciprotein particles in uraemia. Bone 2018; 110: 355-367
• 31 Smith ER, Hanssen E, McMahon LP. et al Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PloS one 2013; 8: e60904
• 32 Jahnen-Dechent W, Heiss A, Schafer C. et al Fetuin-A regulation of calcified matrix metabolism. Circ Res 2011; 108: 1494-1509
• 33 Tiong MK, Cai MMX, Toussaint ND. et al Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function. Sci Rep 2022; 12: 7358
• 34 Herrmann M, Schafer C, Heiss A. et al Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 2012; 111: 575-584
• 35 Köppert S, Büscher A, Babler A. et al Cellular clearance and biological activity of calciprotein particles depend on their maturation state and crystallinity. Front Immunol 2018; 9: 1991
• 36 Koeppert S, Ghallab A, Peglow S. et al Live imaging of calciprotein particle clearance and receptor mediated uptake: role of calciprotein monomers. Front Cell Dev Biol 2021; 9: 633925
• 37 Smith ER, Hewitson TD, Cai MMX. et al A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Sci Rep 2017; 7: 5686
• 38 Hamano T, Matsui I, Mikami S. et al Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010; 21: 1998-2007
• 39 Smith ER, Ford ML, Tomlinson LA. et al Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2012; 27: 1957-1966
• 40 Smith ER, Ford ML, Tomlinson LA. et al Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 2014; 25: 339-348
• 41 Gatate Y, Nakano S, Mizuno Y. et al Mid-term predictive value of calciprotein particles in maintenance hemodialysis patients based on a gel-filtration assay. Atherosclerosis 2020; 303: 46-52
• 42 Tiong MK, Holt SG, Ford ML. et al Serum calciprotein monomers and chronic kidney disease progression. Am J Nephrol 2022; 53: 806-815
• 43 Hashimoto Y, Kato S, Kuro OM. et al Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis. Nephrology (Carlton) 2022; 27: 763-770
• 44 Thiem U, Lenz J, Haller MC. et al The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients. Clin Kidney J 2024; 17: sfae097
• 45 Miura M, Miura Y, Iwazu Y. et al Removal of calciprotein particles from the blood using an adsorption column improves prognosis of hemodialysis miniature pigs. Sci Rep 2023; 13: 15026
• 46 Pasch A, Farese S, Graber S. et al Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752
• 47 Pasch A, Block GA, Bachtler M. et al Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. Clin J Am Soc Nephrol 2017; 12: 315-322
• 48 Zawada AM, Wolf M, Rincon Bello A. et al Assessment of a serum calcification propensity test for the prediction of all-cause mortality among hemodialysis patients. BMC Nephrol 2023; 24: 35
• 49 Bundy JD, Cai X, Mehta RC. et al Serum calcification propensity and clinical events in CKD. Clin J Am Soc Nephrol 2019; 14: 1562-1571
• 50 Bojic M, Koller L, Cejka D. et al Propensity for calcification in serum associates with 2-year cardiovascular mortality in ischemic heart failure with reduced ejection fraction. Front Med (Lausanne) 2021; 8: 672348
• 51 Bojic M, Bielesz B, Cejka D. et al Calcification propensity in serum and cardiovascular outcome in peripheral artery disease. Thromb Haemost 2022; 122: 1040-1046
• 52 Eelderink C, Te Velde-Keyzer CA, Frenay AS. et al Serum calcification propensity and the risk of cardiovascular and all-cause mortality in the general population: the PREVEND study. Arterioscler Thromb Vasc Biol 2020; 40: 1942-1951
• 53 Thiem U, Soellradl I, Robl B. et al The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial. Clin Kidney J 2021; 14: 631-638
• 54 Bressendorff I, Hansen D, Schou M. et al The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease: a randomized, controlled clinical trial. Clin J Am Soc Nephrol 2018; 13: 1373-1380
• 55 Lorenz G, Mayer CC, Bachmann Q. et al Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity-a preliminary study. Nephrol Dial Transplant 2018; 33: 2043-2051
• 56 Dekker M, Pasch A, van der Sande F. et al High-flux hemodialysis and high-volume hemodiafiltration improve serum calcification propensity. PloS one 2016; 11: e0151508
• 57 Cejka D, Thiem U, Blinzler E. et al Citrate-buffered, magnesium-enriched dialysate on calcification propensity in hemodialysis patients – the CitMag study. Kidney Int Rep 2024; 9: 1765-1773
• 58 Pasch A, Jahnen-Dechent W, Smith ER. Phosphate, calcification in blood, and mineral stress: the physiologic blood mineral buffering system and its association with cardiovascular risk. Int J Nephrol 2018; 2018: 9182078